INDEPENDENT VERDICT
Clotine Capital Fund LLC is a Wyoming private investment vehicle associated with founder Dan Abbate and Clotine GM, LLC. Unlike a newly established fund, Clotine has maintained an SEC Form D filing history since 2023 and promotes a customizable investment model focused on private real estate equity, debt and asset-backed opportunities. Its April 2025 amendment reported $14.34 million in securities sold to 68 investors, while a September 2026 filing summary indicates that cumulative reported sales subsequently declined to approximately $12.38 million. This change deserves investigation because an amended offering total should not automatically be interpreted as investment performance, capital loss or investor redemptions. The fund's website also expressly states that its manager is not registered as an investment adviser with the SEC, citing assets below the federal registration threshold. Another material concern involves performance transparency: the sponsor advertises growth in invested capital and earnings paid, but acknowledges that these are gross platform-level figures rather than individual net investment returns. The available evidence supports concrete questions concerning regulatory status, amended fundraising figures, underlying investment quality, related-party compensation and investor liquidity. It does not establish that the fund has committed fraud or violated securities law.
KEY FINDINGS — A MULTIYEAR OFFERING WITH DECLINING REPORTED SALES
The SEC identifies Clotine Capital Fund LLC as a Wyoming limited liability company formed in 2023, with Dan Abbate named as an executive officer. Its April 28, 2025 Form D/A lists a $25 million total offering, $14,339,417 in securities sold, $10,660,583 remaining and 68 investors. The same filing identifies June 21, 2023 as the first sale date and establishes a $25,000 minimum investment. The issuer claims the Rule 506(c) exemption and an Investment Company Act exclusion under Section 3(c)(5), classifying the offering as commercial rather than checking the pooled investment fund industry category. The September 24, 2026 amendment summary reports cumulative securities sold of $12,378,568, compared with $13,433,053 in October 2025 and $14,339,417 in April 2025. The approximately $1.96 million difference from the April 2025 figure is a meaningful disclosure change, but the public figures alone do not explain whether it resulted from corrections, cancellations, revised subscriptions or another reporting adjustment. Investors should request a reconciliation of capital subscribed, capital contributed, withdrawals, distributions and current net asset value. The earlier reported 68 investors and $25,000 minimum should also be distinguished from information that may have changed in the latest amendment. Securities sold is a fundraising disclosure, not a measure of audited investment performance.
MANAGEMENT AND REGULATORY PENETRATION — AN UNREGISTERED SEC ADVISER IS A DISCLOSURE THAT REQUIRES VERIFICATION
Clotine's official website identifies Clotine GM, LLC as the fund's manager and Dan Abbate as its founder. The website states that Clotine GM is not registered as an investment adviser under the Investment Advisers Act of 1940 because its assets under management are below the federal registration threshold. It further states that the manager is not a registered broker-dealer and that Clotine Capital Fund and Dan Abbate are not SEC-registered investment advisers. These disclosures should not be misrepresented as proof of illegal operations: investment adviser registration obligations depend on the precise business activities, assets under management, applicable exclusions and state or federal requirements. Nevertheless, the distinction is important for investors who may incorrectly assume that an SEC Form D filing means the investment manager itself is SEC-registered or subject to the same reporting obligations as a registered investment adviser. The fund's reliance on Rule 506(c) also requires attention because the offering is restricted to verified accredited investors under the applicable exemption. The sponsor's promotional materials, offering documents and subscription verification procedures should be consistent with this framework. Investors should request the manager's legal identity, applicable registration or exemption basis, state regulatory information, ownership structure and written explanation of the entity responsible for investment decisions. SEC Form D submission does not establish that the Commission has approved the manager, reviewed the investment strategy or independently verified the fund's operating controls.
INVESTMENT STRUCTURE — CUSTOMIZABLE DEAL SELECTION DOES NOT ELIMINATE CONCENTRATION RISK
Clotine describes its offering as a customizable, self-directed investment fund in which investors can select individual opportunities through the fund's investment platform. Its current website emphasizes private real estate equity, debt investments, underlying collateral and investments designed to generate current income. Earlier promotional materials likewise describe a structure in which members choose the opportunities to which their capital is allocated. This model creates a different due-diligence problem from a conventional diversified fund: investors must examine both the umbrella investment vehicle and the economics of each selected underlying transaction. Choosing individual deals may provide greater control over investment selection, but can also leave an investor concentrated in a small number of borrowers, properties, operators or related business ventures. The fund's public Form D does not identify a complete portfolio schedule, property-level debt obligations, loan-to-value ratios, independent appraisals, borrower financial statements or the legal priority of each investment. The sponsor's own materials acknowledge that collateral does not guarantee repayment or recovery of invested capital. Investors should determine whether they hold a direct security interest, an indirect interest through the fund or merely contractual rights against an intermediate investment entity. They should also establish whether collateral is independently perfected, whether senior lenders have priority and how enforcement proceeds would be distributed after default. A strategy marketed as asset-backed should be evaluated through actual collateral documentation rather than the presence of real estate or other assets somewhere in the transaction structure.
PERFORMANCE TRANSPARENCY — GROWTH STATISTICS ARE NOT INVESTOR NET RETURNS
Clotine's website presents several operating statistics for the year ended December 31, 2025, including reported year-over-year growth of 40% in investor members, 63% in total capital invested, 60% in available investment deals and 222% in the total dollar amount of earnings paid to investors. These figures may describe expansion in platform activity, but they do not establish that an individual investor earned a 222% return or that the fund's net asset value increased by a comparable percentage. The sponsor expressly states that these figures are presented on a gross basis before applicable fees and expenses and do not represent an individual investor's return or yield. Its website also explains that the annual report is available to verified accredited investors through the investor portal rather than as a complete public financial report. This creates a material limitation for independent researchers attempting to reconcile reported fundraising changes with portfolio value, investor distributions and investment profitability. Investors should request audited annual financial statements where available, a complete schedule of invested capital, realized and unrealized gains, return of principal, investor-level cash flows and fees deducted from distributions. Payments characterized as earnings should be reconciled against operating income, loan interest, asset-sale proceeds and any return of contributed capital. Growth in total distributions can result from an expanding investor base or larger deployed capital and does not independently establish improved investment performance. Historical returns and target yields should be presented separately, with clearly identified investment periods and net-of-fee calculation methods.
CAPITAL MANAGERS AND COMPENSATION — A DISTINCT DISTRIBUTION CONFLICT
The fund's public team page describes opportunities for individuals to become Capital Managers, receive recurring income rather than one-time sales commissions and obtain an ownership or partnership relationship within the management organization. This is a substantive feature of the business model because it introduces potential economic incentives associated with attracting or servicing investors. The April 2025 Form D/A reports zero sales commissions and zero finders' fees and does not identify a compensated broker-dealer in its corresponding sales compensation section. Those entries should not automatically be interpreted as proof that no person or affiliated entity receives compensation connected with fundraising, investor relationships or ongoing fund operations. Equally, the website's description of Capital Manager opportunities does not independently establish that any particular compensation arrangement violates securities law. The appropriate investigation concerns the legal duties performed by Capital Managers, the source of their compensation, whether payments depend on investor commitments and how the arrangement is treated under applicable broker-dealer requirements. Investors should also establish whether compensation is paid by Clotine GM, a related management company, the fund itself or another commercial entity. Any recurring payments, ownership distributions, referral arrangements and transaction-level management fees should be reconciled against the offering documents and fund financial statements. The existence of personnel with economic incentives to attract capital makes independent verification of investment terms particularly important.
LIQUIDITY AND DISTRIBUTION RISK — MONTHLY INCOME IS NOT GUARANTEED
Clotine promotes investments designed to produce recurring income, with monthly or quarterly distributions depending on the underlying deal. However, the official website expressly states that distribution timing, frequency and amounts are investment-specific, are governed by individual deal documents and are not guaranteed. Some investments may fail to produce distributions for extended periods. The fund also acknowledges that its membership interests are illiquid, that no public trading market exists and that investors may be unable to liquidate their investment for an extended period or at all. These disclosures limit the interpretation of marketing references to current cash flow, financial freedom and asset-backed stability. A private real estate or debt position may experience payment interruption because of tenant vacancies, refinancing difficulties, borrower default, property expenses, construction delays or changes in collateral value. Even where an underlying borrower continues making contractual payments, fund-level reserves, expenses and contractual distribution priorities may affect the amount available to individual members. Investors should obtain the specific deal memorandum, operating agreement, subscription agreement and relevant loan or equity investment documents before committing capital. Particular attention should be given to redemption rights, lockup periods, withdrawal notice requirements, capital-call obligations, distribution priority, default procedures and the treatment of investors who elect not to participate in subsequent financing. The ability to choose individual investments does not itself create an enforceable right to withdraw capital whenever an investor wishes.
FINAL ASSESSMENT
Clotine Capital Fund has an identifiable SEC filing history, a functioning official website and a documented private investment offering dating to 2023. Its most important research issues arise from the September 2026 reduction in reported cumulative securities sales, its expressly disclosed SEC investment adviser registration status, the limited public availability of net performance information and the economic relationships within its Capital Manager model. These are matters requiring documentary verification rather than assumptions of misconduct. Investors should obtain an explanation of the amended fundraising figures, current financial statements, complete fee arrangements, investment-level collateral documentation and evidence supporting any claimed return or distribution history. They should also independently verify the manager's applicable regulatory status and distinguish the legal issuer from affiliated management and fundraising entities. The sponsor's reported growth statistics, collateral-backed investment descriptions and historical distributions do not establish guaranteed future income, portfolio liquidity or capital protection. SEC Form D filing is a notice of an exempt offering, not SEC approval, and private fund investors remain exposed to valuation losses, illiquidity, counterparty default and the potential loss of their entire investment.